Co-development and co-promotion agreement for up to five innovative psychiatric and neuroscience productsCo-Development and Co-Promotion Agreement • November 17th, 2022
Long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide.
SECOND AMENDMENT TO AMENDED AND RESTATED CO‑DEVELOPMENT AND CO‑PROMOTION AGREEMENT (APIXABAN)Co-Development and Co-Promotion Agreement • July 28th, 2016 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
THIS SECOND AMENDMENT (this “Amendment”) TO THAT CERTAIN AMENDED AND RESTATED CO‑DEVELOPMENT AND CO‑PROMOTION AGREEMENT (Apixaban), dated as of April 26, 2007, as amended and restated as of August 23, 2007, is made as of March 15, 2012 (the “Effective Date”) by and between BRISTOL‑MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and PFIZER INC., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“COLLABORATOR”). BMS and COLLABORATOR are sometimes referred to herein individually as a “Party” and collectively as the “Parties.
FOURTH AMENDMENT TO AMENDED AND RESTATED CO‑DEVELOPMENT AND CO‑PROMOTION AGREEMENT (APIXABAN)Co-Development and Co-Promotion Agreement • July 28th, 2016 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
THIS FOURTH AMENDMENT (this “Amendment”) TO THAT CERTAIN AMENDED AND RESTATED CO‑DEVELOPMENT AND CO‑PROMOTION AGREEMENT (Apixaban), dated as of April 26, 2007, as amended and restated as of August 23, 2007, is made as of May 18, 2015 (the “Execution Date”) by and between BRISTOL‑MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and PFIZER INC., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“COLLABORATOR”). BMS and COLLABORATOR are sometimes referred to herein individually as a “Party” and collectively as the “Parties.
Promotion and Development Collaborations Between Established PlayersCo-Development and Co-Promotion Agreement • June 16th, 2009
Confidential Treatment RequestedCo-Development and Co-Promotion Agreement • July 28th, 2016 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED CO‑DEVELOPMENT AND CO‑PROMOTION AGREEMENT (the “Agreement”) is made as of April 26, 2007 (the “Execution Date”) and amended and restated as of August 23, 2007, by and between BRISTOL‑MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), and PFIZER INC., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“COLLABORATOR”). BMS and COLLABORATOR are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractCo-Development and Co-Promotion Agreement • March 3rd, 2022
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
Co-development and co-promotion agreement for Relaxin mRNA therapeuticCo-Development and Co-Promotion Agreement • July 11th, 2024
